Table 1 PICO research questions declared by the core team for development of the guidelines
Number | PICO formulation |
|---|---|
RQ 1 | Considering T2T, what would be the best initial therapy, most likely to achieve the treatment target, for the 4 clinical phenotypes of JIA? |
RQ 2 | What is the efficacy and safety of DMARDs? |
RQ 3 | Which DMARDs would be the first treatment option and what is its dose and route of administration? |
RQ 4 | What is the efficacy and safety of NSAID? |
RQ 5 | When NSAIDs should be considered in the management plan? |
RQ 6 | What would be the subsequent step of treatment in case the disease activity remains moderate/high in spite of DMARDs therapy? |
RQ 7 | What is the best choice DMARDs standalone or combination of biologic and DMARDs |
RQ 8 | When steroids therapy should be considered in the management plan and what its dose and route of administration? |
RQ 9 | What is the best approach for switching between biologic therapies? |
RQ 10 | What is the best schedule for monitoring disease activity and how frequent? |
RQ 11 | How treatment tapering or withdrawal can be undertaken? |
RQ 12 | What should be the treatment targets? |
RQ 13 | When physical therapy should be considered in the management pathway? |
RQ 14 | What are the treatment options for refractory polyarticular/oligoarticular JIA? |
RQ 15 | What are the treatment options for refractory systemic JIA? |
RQ 16 | What are the treatment options for refractory enthesitis/spondyloarthritis? |
RQ 17 | What are the treatment options for refractory uveitis? |